This study investigates the genetic evolution of pancreatic cancer and the timing of distant metastasis. Researchers analyzed seven pancreatic cancer metastases and found that the genetic mutations responsible for distant metastases were already present in the primary tumor but had evolved from the original, non-metastatic clone. The study revealed that the majority of somatic mutations in pancreatic cancers occur before the development of metastatic lesions. The genetic evolution of pancreatic cancer was quantified, showing that the initiating mutation occurs at least a decade before the birth of the parental, non-metastatic clone. It takes at least five more years for the acquisition of metastatic ability, and patients die an average of two years after the metastatic cells begin to grow. The study also found that the primary tumor is a mixture of numerous subclones, each of which has independently expanded to constitute a large number of cells. These subclones give rise to metastases in different organs, such as the liver, lung, and peritoneum. The genetic heterogeneity of metastases reflects that within the primary tumor. The researchers used genomic sequencing and other techniques to analyze the mutations in the primary tumor and metastases, identifying two categories of mutations: founder mutations, which are common to all samples from a given patient, and progressor mutations, which are present in one or more metastases but not in the parental clone. The study also estimated the timing of the development of pancreatic cancer stages, showing that the average time between the initiation of tumorigenesis and the birth of the cell giving rise to the parental clone is about 11.7 years. The average time between the birth of the cell giving rise to the index lesion and the patient's death is about 2.7 years. These findings suggest that there is a large window of opportunity for early detection of pancreatic cancer before it becomes metastatic. The study highlights the importance of early detection and the need for advanced imaging methods and blood tests to detect cancer-specific proteins, transcripts, or genes for non-invasive early detection. The results provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window for early detection to prevent deaths from metastatic disease.This study investigates the genetic evolution of pancreatic cancer and the timing of distant metastasis. Researchers analyzed seven pancreatic cancer metastases and found that the genetic mutations responsible for distant metastases were already present in the primary tumor but had evolved from the original, non-metastatic clone. The study revealed that the majority of somatic mutations in pancreatic cancers occur before the development of metastatic lesions. The genetic evolution of pancreatic cancer was quantified, showing that the initiating mutation occurs at least a decade before the birth of the parental, non-metastatic clone. It takes at least five more years for the acquisition of metastatic ability, and patients die an average of two years after the metastatic cells begin to grow. The study also found that the primary tumor is a mixture of numerous subclones, each of which has independently expanded to constitute a large number of cells. These subclones give rise to metastases in different organs, such as the liver, lung, and peritoneum. The genetic heterogeneity of metastases reflects that within the primary tumor. The researchers used genomic sequencing and other techniques to analyze the mutations in the primary tumor and metastases, identifying two categories of mutations: founder mutations, which are common to all samples from a given patient, and progressor mutations, which are present in one or more metastases but not in the parental clone. The study also estimated the timing of the development of pancreatic cancer stages, showing that the average time between the initiation of tumorigenesis and the birth of the cell giving rise to the parental clone is about 11.7 years. The average time between the birth of the cell giving rise to the index lesion and the patient's death is about 2.7 years. These findings suggest that there is a large window of opportunity for early detection of pancreatic cancer before it becomes metastatic. The study highlights the importance of early detection and the need for advanced imaging methods and blood tests to detect cancer-specific proteins, transcripts, or genes for non-invasive early detection. The results provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window for early detection to prevent deaths from metastatic disease.